首页 / 院系成果 / 成果详情页

Low-dose baricitinib plus danazol in primary immune thrombocytopenia: a randomized, controlled phase 2 trial 期刊论文

编号：

F40734E0E59C309C409860DA1A4CED1B
作者：

Zhao, Peng#^[1,2,3,4]An, ZhuoYu#^[1,2,3,4]Fu, HaiXia^[1,2,3,4];Wang, Yang^[5,6];Feng, GuoShuang^[7];Liu, HuiXin^[8];Liu, DaiHong^[9,10];Liu, Yi^[11];Zhou, HeBing^[12];Liu, Hui^[13];Wang, Zhao^[14];Dong, YuJun^[15];Jing, HongMei^[16];Li, ZhenLing(李振玲)^[17]Li, LiHong^[18];Dou, LiPing^[9,10];Huang, QiuSha^[1,2,3,4];Wu, Jin^[1,2,3,4];Yang, LiPing^[1,2,3,4];Jin, Yue^[1,2,3,4];Li, ZhiXue^[1,2,3,4];Wang, ChenCong^[1,2,3,4];Chen, Qi^[1,2,3,4];Zhu, XiaoLu^[1,2,3,4];He, Yun^[1,2,3,4];Zhang, YuanYuan^[1,2,3,4];Jiang, Qian^[1,2,3,4];Jiang, Hao^[1,2,3,4];Lu, Jin^[1,2,3,4];Chang, YingJun^[1,2,3,4];Zhao, XiangYu^[1,2,3,4];Huang, XiaoJun*^[1,2,3,4]Zhang, XiaoHui*^[1,2,3,4]
语种：

英文
期刊：

NATURE COMMUNICATIONS ISSN：2041-1723 2026 年 17 卷 1 期 ; JUL 25
收录：
摘要：

This multicenter, randomized, controlled study was conducted to explore the safety and efficacy of low-dose baricitinib plus danazol for ITP patients who had failed corticosteroids and at least one recommended subsequent treatment. Participants were randomly assigned to receive baricitinib plus danazol (n = 108) or danazol alone (n = 108) by a central, interactive web-based system. Patients and caregivers were not blinded to group assignment. Efficacy assessments were performed in the intention-to-treat population by investigators blinded to group assignment. The primary endpoint was 6-month durable response. Forty-nine (45.4%) patients in the combination arm and 22 (20.4%) patients in the monotherapy arm achieved 6-month durable response (P < 0.001). The safety analysis set included patients who received at least one dose of study medication (n = 108 in the combination arm and n = 105 in the monotherapy arm). Fifty-two (48.1%) patients receiving baricitinib plus danazol and 47 (44.7%) patients receiving danazol alone reported at least one adverse event. Each arm reported two patients who developed an adverse event causing study discontinuation and one patient who developed a grade 3 or more severe adverse event. Low-dose baricitinib plus danazol might be a novel option for difficult-to-treat ITP.
推荐引用方式
GB/T 7714：

Zhao Peng,An Zhuo-Yu,Fu Hai-Xia, et al. Low-dose baricitinib plus danazol in primary immune thrombocytopenia: a randomized, controlled phase 2 trial [J].NATURE COMMUNICATIONS,2026,17(1).
APA：

Zhao Peng,An Zhuo-Yu,Fu Hai-Xia,Wang Yang,&Zhang Xiao-Hui.(2026).Low-dose baricitinib plus danazol in primary immune thrombocytopenia: a randomized, controlled phase 2 trial .NATURE COMMUNICATIONS,17(1).
MLA：

Zhao Peng, et al. "Low-dose baricitinib plus danazol in primary immune thrombocytopenia: a randomized, controlled phase 2 trial" .NATURE COMMUNICATIONS 17,1(2026).
入库时间：

2026/9/9 9:17:55
更新时间：

2026/9/9 9:17:55

浏览次数：4  下载次数：0

分享到：

浏览次数：4

下载次数：0

打印次数：0